tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: ObsEva SA (OBSV), Inozyme Pharma (INZY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSVResearch Report), Inozyme Pharma (INZYResearch Report) and Regeneron (REGNResearch Report) with bullish sentiments.

ObsEva SA (OBSV)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $15.00. The company’s shares closed last Friday at $1.43, close to its 52-week low of $1.35.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -33.0% and a 15.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Oncternal Therapeutics, and Inovio Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ObsEva SA with a $15.00 average price target.

See the top stocks recommended by analysts >>

Inozyme Pharma (INZY)

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Inozyme Pharma and a price target of $33.00. The company’s shares closed last Friday at $6.10, close to its 52-week low of $5.33.

According to TipRanks.com, White is a 1-star analyst with an average return of -2.0% and a 30.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inozyme Pharma with a $28.00 average price target.

Regeneron (REGN)

H.C. Wainwright analyst Michael King maintained a Buy rating on Regeneron today and set a price target of $843.00. The company’s shares closed last Friday at $622.96.

According to TipRanks.com, King is a 4-star analyst with an average return of 12.1% and a 45.2% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Werewolf Therapeutics, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $707.29 average price target, a 15.9% upside from current levels. In a report issued on January 31, Truist Financial also maintained a Buy rating on the stock with a $754.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OBSV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed